News Samsung Biologics agrees $1.81bn takeover of PolyPeptide Samsung Biologics has agreed to buy PolyPeptide, a Swiss CDMO, in what is thought to be South Korea's largest biopharma acquisition to date.
R&D Setting the standard for sustainability in pharma Sustainability has become a crucial pillar in pharmaceutical development, with environmental concerns and resource management demanding immediate attention from organisations of all sizes a
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.